RT Journal Article
SR Electronic
T1 High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20143214
DO 10.1101/2020.07.01.20143214
A1 Franke, Christiana
A1 Ferse, Caroline
A1 Kreye, Jakob
A1 Reincke, S Momsen
A1 Sanchez-Sendin, Elisa
A1 Rocco, Andrea
A1 Steinbrenner, Mirja
A1 Angermair, Stefan
A1 Treskatsch, Sascha
A1 Zickler, Daniel
A1 Eckardt, Kai-Uwe
A1 Dersch, Rick
A1 Hosp, Jonas
A1 Audebert, Heinrich J.
A1 Endres, Matthias
A1 Ploner, Christoph J.
A1 Prüss, Harald
YR 2020
UL http://medrxiv.org/content/early/2020/07/06/2020.07.01.20143214.abstract
AB COVID-19 intensive care patients occasionally develop neurological symptoms. The absence of SARS-CoV-2 in most cerebrospinal fluid (CSF) samples suggests the involvement of further mechanisms including autoimmunity. We therefore determined whether anti-neuronal or anti-glial autoantibodies are present in eleven consecutive severely ill COVID-19 patients presenting with unexplained neurological symptoms. These included myoclonus, cranial nerve involvement, oculomotor disturbance, delirium, dystonia and epileptic seizures. Most patients showed signs of CSF inflammation and increased levels of neurofilament light chain. All patients had anti-neuronal autoantibodies in serum or CSF when assessing a large panel of autoantibodies against intracellular and surface antigens relevant for central nervous system diseases using cell-based assays and indirect immunofluorescence on murine brain sections. Antigens included proteins well-established in clinical routine, such as Yo or NMDA receptor, but also a variety of specific undetermined epitopes on brain sections. These included vessel endothelium, astrocytic proteins and neuropil of basal ganglia, hippocampus or olfactory bulb. The high frequency of autoantibodies targeting the brain in the absence of other explanations suggests a causal relationship to clinical symptoms, in particular to hyperexcitability (myoclonus, seizures). While several underlying autoantigens still await identification in future studies, presence of autoantibodies may explain some aspects of multi-organ disease in COVID-19 and can guide immunotherapy in selected cases.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthis is a case series and not a clinical trialFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This case series is a retrospective analysis of cerebrospinal fluid in COVID-19 patients. Research consent was obtained from all patients or their legal representatives. Ethic amendement has been obtained for data collection in patients with COVID-19 (ethics committee approval, Berlin: EA2/066/20, Freiburg: 153/20, laboratory analysis Berlin: EA 1/258/18)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available by request.